To save lives through rigorous science, data-driven decision making, and innovative medicines.


Sensei Biotherapeutics is developing revolutionary immune-modulating agents to solve the toughest problems in the fields of immunology, oncology and infectious diseases. Our unique approach starts with a library of vaccines and nanobodies that can be combined in almost limitless ways to create an powerful, coordinated, and nuanced multi-modal immune response against a pathological target.

Our lead program, SNS-301, targets the tumor antigen, Aspartyl beta Hydroxylase (ASPH), and has shown excellent safety and clinical benefit in Phase 1 patient trials, and is currently in Phase 2 at multiple clinical sites across the USA. Additional programs are in various stages of preclinical development.

Located in Gaithersburg Maryland and Boston Massachusetts, we have state-of-the-art laboratories for discovery, development, and manufacturing of biological products, as well as clinical testing.